ARTICLE | Clinical News
RHB-102 regulatory update
March 4, 2013 8:00 AM UTC
RedHill said it plans to submit an NDA to FDA in 4Q13 for RHB-102 to prevent nausea and vomiting in cancer patients following its Type B pre-NDA meeting with the agency. Last year, the company reporte...